Search hospitals > Virginia > Fredericksburg
Hematology Oncology Associates of Fredericksburg Inc
Claim this profileFredericksburg, Virginia 22408
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
65 reported clinical trials
8 medical researchers
Summary
Hematology Oncology Associates of Fredericksburg Inc is a medical facility located in Fredericksburg, Virginia. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Hematology Oncology Associates of Fredericksburg Inc is involved with conducting 65 clinical trials across 124 conditions. There are 8 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Khalid Matin, and Masey M. Ross.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Andrew Poklepovic, MDVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Tumors
33 reported clinical trials
82 drugs studied
Sarah W. Gordon, DOVirginia Commonwealth University/Massey Cancer Center8 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
54 drugs studied
Khalid MatinVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
13 reported clinical trials
29 drugs studied
Masey M. RossVirginia Commonwealth University/Massey Cancer Center1 year of reported clinical research
Expert in Breast Cancer
Studies Cancer
12 reported clinical trials
26 drugs studied
Clinical Trials running at Hematology Oncology Associates of Fredericksburg Inc
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Anal Squamous Cell Carcinoma
Anal Cancer
Tumors
ALK Gene Rearrangement
Multiple Myeloma
Skin Cancer
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Bria-IMT + CPI
for Advanced Breast Cancer
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Recruiting2 awards Phase 36 criteria
ARV-471
for Breast Cancer
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Hematology Oncology Associates of Fredericksburg Inc?
Hematology Oncology Associates of Fredericksburg Inc is a medical facility located in Fredericksburg, Virginia. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Hematology Oncology Associates of Fredericksburg Inc is involved with conducting 65 clinical trials across 124 conditions. There are 8 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Khalid Matin, and Masey M. Ross.